Regorafenib Plus for third-line treatment in metastatic colorectal cancer: A real-world study

被引：0
|
作者：
Yisilamu, Patiguli [1 ]
Yao, Jiannan [1 ]
Ge, Yang [1 ]
机构：
[1] Capital Med Univ, Beijing Chaoyang Hosp, Dept Oncol, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15562
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study
    Tasci, Elif Senocak
    Oyan, Basak
    Sonmez, Ozlem
    Mutlu, Arda Ulas
    Atci, Muhammed Mustafa
    Oner, Irem
    Cinkir, Havva Yesil
    Eryilmaz, Melek Karakurt
    Balcik, Onur Yazdan
    Paksoy, Nail
    Salim, Derya Kivrak
    Ozen, Mirac
    Ozcelik, Melike
    Arican, Ali
    Inal, Ali
    Akagunduz, Baran
    Aydin, Dincer
    Ozer, Leyla
    Turhal, Nazim Serdar
    Gulmez, Ahmet
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [42] Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer
    Kimura, Michio
    Usami, Eiseki
    Teramachi, Hitomi
    Yoshimura, Tomoaki
    [J]. ANTICANCER RESEARCH, 2020, 40 (03) : 1605 - 1611
  • [43] Current Options for Third-Line Treatment of Metastatic Colorectal Cancer: Discussion
    Grothey, Axel
    Marshall, John L.
    Seery, Tara E.
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (03) : 13 - 14
  • [44] Regorafenib as third-line treatment for refractory metastatic colorectal cancer (mCRC): Experience of Hospital de Navarra clinical practice
    Velasco Elena, Mata
    De lascoiti Angela, Fernandez
    Arnaiz Irene, Gil
    Lucia, Teijeira
    Ruth, Vera
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [45] Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
    Tasci, Elif Senocak
    Oyan, Basak
    Soenmez, Oezlem
    Mutlu, Arda Ulas
    Atci, Muhammed Mustafa
    Sakin, Abdullah
    Oener, Irem
    Cinkir, Havva Yesil
    Eryilmaz, Melek Karakurt
    Caglayan, Dilek
    Balcik, Onur Yazdan
    Paksoy, Nail
    Karabulut, Senem
    Salim, Derya Kivrak
    Bilir, Cemil
    Oezen, Mirac
    Oezcelik, Melike
    Arican, Ali
    Akaguenduez, Baran
    Inal, Ali
    Aydin, Dincer
    Oezer, Leyla
    Guelmez, Ahmet
    Turhal, Nazim Serdar
    Esen, Selin Aktuerk
    Algin, Efnan
    Akbas, Sinem
    Iriagac, Yakup
    Sakalar, Teoman
    Uenal, Caglar
    Er, Oezlem
    Secmeler, Saban
    Bozkurt, Mustafa
    [J]. BMC CANCER, 2024, 24 (01)
  • [46] Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
    Elif Şenocak Taşçı
    Başak Oyan
    Özlem Sönmez
    Arda Ulaş Mutlu
    Muhammed Mustafa Atcı
    Abdullah Sakin
    İrem Öner
    Havva Yeşil Çınkır
    Melek Karakurt Eryılmaz
    Dilek Çağlayan
    Onur Yazdan Balçık
    Nail Paksoy
    Senem Karabulut
    Derya Kıvrak Salim
    Cemil Bilir
    Miraç Özen
    Melike Özçelik
    Ali Arıcan
    Baran Akagündüz
    Ali İnal
    Dinçer Aydın
    Leyla Özer
    Ahmet Gülmez
    Nazım Serdar Turhal
    Selin Aktürk Esen
    Efnan Algın
    Sinem Akbaş
    Yakup İriağaç
    Teoman Şakalar
    Çağlar Ünal
    Özlem Er
    Şaban Seçmeler
    Mustafa Bozkurt
    [J]. BMC Cancer, 24
  • [47] Treatment patterns and outcomes of patients with metastatic colorectal cancer in third-line and beyond systemic therapy: Real-world data from a setting with limited resources
    Jacome, Alexandre A.
    Gil, Roberto Almeida
    de Moraes, Eduardo Dias
    Peixoto, Renata D'Alpino
    Canedo, Jorge Alexandre
    Passarini, Thais
    Gil, Mariana
    Pereira, Sabrina
    Amorim, Larissa
    Prolla, Gabriel
    Freitas, Laura
    Coelho, Fernanda
    Paiva, Isabela
    Paes, Rafael
    Cruz, Heloisa
    Costa e Silva, Matheus
    Ferreira, Carlos Gil
    Ferrari, Bruno Lemos
    Garicochea, Bernardo
    Dienstmann, Rodrigo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [48] Real-world outcomes in metastatic colorectal patients receiving regorafenib treatment in China
    Qu, W.
    Jiang, Z.
    Liu, Z.
    Zhu, L.
    Chen, X.
    Liu, B.
    Zhao, Y.
    Li, S.
    Yan, H.
    Qu, X.
    Zang, A.
    Sun, Y.
    Zhou, A.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S335 - S336
  • [49] COST EFFECTIVENESS OF FRUQUINTINIB VERSUS REGORAFENIB AS THE THIRD-LINE THERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER IN CHINA
    Xin, G.
    Li, H. C.
    Peng, C.
    Wang, N.
    Ma, X.
    Xiong, X. M.
    Ma, A. X.
    [J]. VALUE IN HEALTH, 2019, 22 : S83 - S83
  • [50] Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer
    Zhong, Jiayun
    Liu, Yu
    Fu, Qian
    Huang, Dan
    Gong, Wenjun
    Zou, Jian
    [J]. CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 593 - 602
12345